SciSparc Ltd.: A Pathbreaking Pharma Play Catering To Central Nervous System Disorders

The sub-domain of cannabinoid technologies within the pharma world is a relatively less explored blue ocean. These technologies have immense application for the treatment of a wide variety of disorders, particularly those catering to the central nervous system. Our small-cap pick for the day is a company that has made ground-breaking research in using cannabinoid technologies for developing treatments of various disorders associated with the CNS such as Tourette Syndrome, Alzheimer’s disease, and many more – SciSparc Ltd. (NASDAQ:SPRC). The company uses the endocannabinoid system as its primary platform and has a wide range of novel compounds, developed by enhancing existing compounds with its proprietary technologies, to develop effective treatments for disorders that have no cure today.

Company Overview

SciSparc Ltd. is a clinical-stage pharmaceutical company specializing in drug development associated with cannabinoid molecules. Its drug development programs include SCI-110 for Tourette syndrome, Alzheimer’s disease and agitation, SCI-160 for pain, and SCI-210 for autism spectrum disorder and Status Epilepticus.  The company is developing and commercializing SCI-110in collaboration with Procaps. It also has a pre-clinical study with the Sheba Fund for Health Services and Research in Israel to evaluate the SCI-210 drug development program for the treatment of Status Epilepticus; and a Phase 2a clinical trial with the Israeli Medical Center for Alzheimer’s disease to assess the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer’s disease and agitation. The synergistic effect observed in the way the endocannabinoid system operates, first described by Israeli scientists Shimon Ben-Shabat and Raphael Mechoulam in 1998, is at the core of SciSparc’s research and development platforms.  This area of  study  is based on the idea that the cannabinoids found in cannabis interact synergistically to affect the body across multiple targets, various benefits. With this work, SciSparc is addressing a number of indications that have a wide impact and unmet medical need. It is a Tel Aviv, Israel-based company.

The SCI-110 Platform

SciSparc’s core drug platform, the SCI-110 includes a number of indications that the company is developing, with clinical testing of the new dosage form for Tourette Syndrome. The company is mainly evaluating SCI-110 in Tourette patients which is where it has made significant progress and advanced beyond the Phase 2a of clinical trials. An average tic reduction of 21% was reported across the entire sample in a Phase 2a clinical trial of SCI-110 conducted in collaboration with Yale University ,and the medication was generally well-tolerated. Within the Phase 2b randomized controlled trial, SciSparc plans to assess the safety, efficacy, and tolerability of SCI-110. The overall potential benefit is expected to be improved oral administration efficiency, allowing for lower dosage and fewer side effects and adverse events.

Large Addressable Market

As per the research of Mordor Intelligence, North America is the largest global market for the treatment of Tourette Syndrome. As per the data of a U.S. CDC study, 1 of every 360 (0.3%) children between 6 years to 17 years of age in the U.S. have received a diagnosis of Tourette Syndrome with around 37% having been reported as having moderate or severe forms of the condition. The global Tourette Syndrome market is expected to grow at a rate of 10.6% until 2026 implying a large addressable market for SciSparc’s SCI-110. Final Thoughts

Source: TradingView

SciSparc is a zero-revenue player but its pipeline is highly diversified and it is very close to starting an active revenue stream through the commercial production and sale of the CannAmide offering. The management is expected to continue developing its pipeline in the coming years. SciSparc’s IP portfolio consists of patent and provisional assignments, enabling the company to capitalize on the economic opportunity for its products within the company’s forecasted time frame. Overall, we are extremely bullish on SciSparc and we believe that it is an extremely promising pharma investment at current levels.


This website is a wholly owned subsidiary of Salesparq, LLC, herein referred to as Salesparq, LLC. Our publications are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We may receive compensation for this article on a PPC basis as an affiliate. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.PLEASE NOTE WELL: Salesparq, LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.Release of Liability: Through use of this website viewing or using you agree to hold Salesparq, LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Salesparq, LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Salesparq, LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead Salesparq, LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Salesparq, LLC is compliant with the Can Spam Act of 2003. Salesparq, LLC does not offer such advice or analysis, and Salesparq, LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.In preparing this publication, Salesparq, LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. Salesparq, LLC has not been compensated for this article. The advertisements in this website are believed to be reliable, however, Salesparq, LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. Salesparq, LLC is not responsible for any claims made by the companies advertised herein, nor is Salesparq, LLC responsible for any other promotional firm, its program or its structure. Salesparq, LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.
Show More

Related Articles

Back to top button